New pill for POU2F3-positive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new pill (FHD-286) that targets a specific marker in small cell lung cancer called POU2F3. The drug aims to stop cancer growth in patients whose tumors have this marker and who have already tried standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer that has grown or returned after platinum-based chemotherapy (with or without immunotherapy).
- Your tumor must show high levels of a protein called POU2F3 (more than 50% of cells).
- You have at least one tumor that can be measured on scans.
- You are generally doing well (ECOG performance status 0 or 1).
- Your blood counts, liver and kidney function, and heart function are within acceptable ranges.
- You are willing to swallow pills and follow study restrictions (e.g., avoid certain medications and foods).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.